Patients with low‐risk MDS exhibit an ido/tph1 enzyme activity imbalance which regulates tryptophan by indoleamine 2,3‐dioxygenase (IDO) and tryptophan 2,3‐dioxygenase (TDO).21 This evidence concerns the gene IDO1 and myelodysplastic syndrome.